back to the overview
Ad-hoc release; Berlin, August 8, 2007
MOLOGEN AG: Treatment permission granted for cancer therapy in India
License partner ONCO Life Sciences starts marketing activities
The Berlin-based biotechnology company MOLOGEN AG has been informed by its license partner ONCO Life Sciences Pvt. Ltd., India, that the respective authorities have granted treatment permission for MOLOGEN’S cell-based gene therapy. This innovative cancer therapy can currently be used for the treatment of renal cell carcinoma, colon, breast, and lung cancer.
At the end of 2006, MOLOGEN had granted licensing and marketing rights for its cancer therapy for India to ONCO Life Sciences. In the context of the agreement, MOLOGEN had received an upfront payment of EUR 2.1 million.
MOLOGEN will receive further payments for the supply of the individualized therapy components to ONCO Life Sciences. MOLOGEN has completed all necessary measures in the areas of production and logistics to provide immediate supply to India. The importation of the components will be free of customs duties.
In advance to the treatment permission, the network of Indian oncologists („ELITE Network“) has been educated about the mode of action, the use and the advantages of MOLOGEN’S cell-based gene therapy. On the basis of single treatment permissions, first patients had been treated in Mumbai and Delhi.
"We are very pleased by the treatment permission for our individualized cell-based gene therapy against major cancer diseases", said Prof Burghardt Wittig, Chief Executive Officer of MOLOGEN AG. "This innovative and straight-forward decision of the Indian Department of Biotechnology impressively confirms our development and commercialization concept for the cell-based therapy approach in the treatment of cancer. It could also serve as reference for further applications in other countries."
MOLOGEN AG is a listed biopharmaceutical company with headquarters in Berlin (Frankfurt Stock Exchange, Regulated Market, ISIN DE0006637200). On the basis of patented technologies (MIDGE and dSLIM), MOLOGEN develops DNA-based vaccines and therapeutic agents for the prevention and treatment of a wide range of serious illnesses.
Disclaimer concerning prognoses
Certain statements in this communication contain formulations or terms referring to the future or future developments, as well as negations of such formulations or terms, or similar terminology. These are described as forward-looking statements. In addition, all information in this communication regarding planned or future results of business segments, financial classification numbers, developments of the financial situation, or other financial or statistical data contains such forward-looking statements. The company cautions prospective investors not to rely on such forward-looking statements as certain prognoses of actual future events and developments. The company is neither responsible nor liable for these forward-looking statements. It is not responsible for updating such information, which only represents the state of affairs on the day of publication.
back to the overview